NFKB1 and Miyoshi myopathy: Bortezomib enhanced constitutive NF-κB activity via activation of the canonical pathway, which suggested that bortezomib-induced cytotoxicity might not be completely ascribed to the inhibition of canonical NF-κB activity in MM [23, 31].